Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Prog Cardiovasc Dis. 2012 Nov-Dec;55(3):274-81. doi: 10.1016/j.pcad.2012.10.007.

Life-saving devices reach the end of life with heart failure.

Author information

  • 1University of Colorado School of Medicine, Aurora, CO 80045, USA. Daniel.matlock@ucdenver.edu

Abstract

The new millennium has seen a dramatic increase in use of potentially life-prolonging devices such as implantable cardioverter-defibrillators (ICDs) and ventricular assist devices (VADs) among patients with advanced heart failure. Most patients who receive these devices will have them in place when they die. Clinicians who care for these patients must commit through the entire course of therapy, including the end-of-life. Discussions about device deactivation should be the standard of care and this discussion should take place prior to implantation, during annual heart failure reviews, after major milestones, and when the end-of-life appears to be approaching. Turning off ICDs and turning off VADs in response to patient or proxy requests are legally the same although they may be perceived differently, as disconnection of the VAD is more likely to cause immediate death. This article discusses the evidence around device deactivation at the end-of-life and offers suggestions for improvement.

Copyright © 2012 Elsevier Inc. All rights reserved.

PMID:
23217431
[PubMed - indexed for MEDLINE]
PMCID:
PMC3523274
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk